Life-threatening drug interactions: what the physician needs to know

被引:30
作者
Day, Richard O. [1 ,2 ,3 ]
Snowden, Leone [4 ]
McLachlan, Andrew J. [5 ,6 ]
机构
[1] St Vincents Hosp, Dept Clin Pharmacol & Toxicol, Sydney, NSW, Australia
[2] Univ New South Wales, Sch Med Sci, Med, Sydney, NSW, Australia
[3] Univ New South Wales, St Vincents Clin Sch, Med, Sydney, NSW, Australia
[4] New South Wales Medicines Informat Ctr, Sydney, NSW, Australia
[5] Univ Sydney, Fac Pharm, Sydney, NSW, Australia
[6] Concord Hosp, Ctr Educ & Res Ageing, Sydney, NSW, Australia
基金
英国医学研究理事会; 澳大利亚研究理事会;
关键词
drug-drug interactions; adverse drug reactions; adverse drug events; pharmacokinetic drug interactions; pharmacodynamic drug interactions; cytochrome P 450 metabolism; TYROSINE KINASE INHIBITORS; CYTOCHROME-P450; 3A4; PREVALENCE; DIGOXIN; PHARMACOKINETICS; AZATHIOPRINE; ALLOPURINOL; RELEVANCE; MEDICINES; TOXICITY;
D O I
10.1111/imj.13404
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adverse drug-drug interactions are a significant cause of adverse events and outcomes. Their incidence is rising, with more patients taking more drugs, and newer, more precise but often more hazardous drugs becoming available. Despite considerable information, including computerised alerts about potential adverse drug-drug interactions, prescribers increasingly override alerts, possibly symptomatic of the immense problem of evaluating the risk of an interaction in a particular patient. Many reports emanate from small studies often of normal and young volunteers, entirely different from the real world where, more often, older patients with multiple health conditions are receiving many more than the two drugs identified in the drug interaction report. Focusing on those drug-drug interactions that are clinically relevant is necessary, and increasingly, tools and reliable sources of this information are easily accessible.
引用
收藏
页码:501 / 512
页数:12
相关论文
共 66 条
[1]   Psychotropic Drug-Drug Interactions Involving P-Glycoprotein [J].
Akamine, Yumiko ;
Yasui-Furukori, Norio ;
Ieiri, Ichiro ;
Uno, Tsukasa .
CNS DRUGS, 2012, 26 (11) :959-973
[2]   Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products [J].
Anderson, Gail D. ;
Chan, Lingtak-Neander .
CLINICAL PHARMACOKINETICS, 2016, 55 (11) :1353-1368
[3]  
Beach SR, 2013, PSYCHOSOMATICS, V54, P1, DOI 10.1016/j.psym.2012.11.001
[4]   Determinants of potential drug-drug interaction associated dispensing in community pharmacies in the Netherlands [J].
Becker, Matthijs L. ;
Caspers, Peter W. J. ;
Kallewaard, Marjon ;
Bruinink, Riekert J. ;
Kylstra, Nico B. ;
Heisterkamp, Siem ;
De Valk, Vincent ;
Veen, Andre A. van der ;
Stricker, Bruno H. Ch. .
PHARMACY WORLD & SCIENCE, 2007, 29 (02) :51-57
[5]   Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies [J].
Beijer, HJM ;
de Blaey, CJ .
PHARMACY WORLD & SCIENCE, 2002, 24 (02) :46-54
[6]   Statin drug interactions and related adverse reactions [J].
Bellosta, Stefano ;
Corsini, Alberto .
EXPERT OPINION ON DRUG SAFETY, 2012, 11 (06) :933-946
[7]   Drug-induced hypoglycemic coma in 102 diabetic patients [J].
Ben-Ami, H ;
Nagachandran, P ;
Mendelson, A ;
Edoute, Y .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (03) :281-284
[8]   Clinical Pharmacology in Research, Teaching and Health Care [J].
Orme, Michael ;
Sjoqvist, Folke .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 107 (01) :531-559
[9]   Prevalence of Alcohol-Interactive Prescription Medication Use Among Current Drinkers: United States, 1999 to 2010 [J].
Breslow, Rosalind A. ;
Dong, Chuanhui ;
White, Aaron .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2015, 39 (02) :371-379
[10]   PRACTICE POINTER Serotonin syndrome [J].
Buckley, Nicholas A. ;
Dawson, Andrew H. ;
Isbister, Geoffrey K. .
BMJ-BRITISH MEDICAL JOURNAL, 2014, 348